1. Diagnose en eerste behandeling van longkanker
Pasiënt Lu is gediagnoseer met long-adenokarsinoom en limfkliermetastase op 26 Augustus 2005. 'n Linker-onder-lobektomie is op 22 September 2005 uitgevoer. Karboplatien gekombineer met taksotere is 4 keer na die operasie gebruik. Op 3 Augustus 2007, as gevolg van pleurale effusie, is bevestig dat die diagnose herhalend is, en sy is met Tarceva behandel (die aantal siklusse is onbekend). Op 8 Januarie 2008 is die kankervordering met die herondersoek gevind, en toe is Tarceva-behandeling gestaak en is Libita-behandeling vir 16 siklusse begin. Terselfdertyd is vertebrale heupmetastase gevind en 4 siklusse van Zetai is uitgevoer.
2. Die toestand is onder beheer, die eerste keer om aan kliniese proewe deel te neem.
In July 2010, Mr. Lu reexamined a large area of brain metastasis and found dozens of small lesions in the brain. He also tested positive for the EML4-ALK fusion gene at the University of Chicago School of Medicine. The whole brain radiation therapy was then used to control the lesions, and the second phase of crizotinib drug trial was started at St. Louis University Hospital. During the treatment, the condition was stably controlled, but a re-examination in May 2012 found that the cancer had progressed slightly, and the tumor was suspected to be resistant to crizotinib. He stopped crizotinib on July 18, 2012.
3. In die tweede kliniese proef het die gewas duidelik verdwyn.
On August 6, 2012, Mr. Lu participated in the AP26113 drug kliniese proef at Denver Hospital. In October, the PET examination showed that the tumor disappeared and the gewas in die brein decreased and became large.
4. Ontdek seldsame geenmutasies en sien uit daarna om aan nuwe kliniese proewe deel te neem
Herondersoek in Julie 2014, die hele liggaam PET het getoon: Breinletsels was basies stabiel, en bors het duidelike vordering gehad. Op 12 Mei 2014 is die vermoedelike anti-AP26113 limf (3 selle, grootste 1.1 cm) gekweekte sellyne by die Massachusetts Algemene Hospitaal uitgevoer en het voortgegaan om AP26113 te neem.
In August 2014, the doctor called and found that Mr. Lu’s new tumor tissue sequencing detected rare or unseen mutations. This mutation was only reported in ALK-positive children’s neuroblastoom and inflammatory myofibroblastoma. Previous research reports and medical evidence have shown that crizotinib cannot cope with the resistant neuroblastoma caused by this mutation. New genetic test results indicate that Mr. Lu may need to find new drugs for treatment.
On December 8, 2014, after a doctor’s analysis and decision, Mr. Lu was approved to increase the dosage of AP26113 and changed it to 240 mg per day, so the drug replacement plan was temporarily delayed. After observing the efficacy, he decided whether to change the drug and participate in other clinical trials. The patient learned through the hospital that NIVOLUMAB monoclonal antibody immunotherapie phase 3/4 drug test is recruiting lung cancer patients on a large scale, and Mr. Lu is fully confident of the future anti-cancer.
